Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Brief Report: A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of Apilimod Mesylate, an Interleukin-12/Interleukin-23 Inhibitor, in Patients With Rheumatoid Arthritis
Finally, the more buried cysteines, C79 (Fig
Several outcomes remain conditional until intake review and fulfillment steps are completed
MEK inhibitor AZD6244 induces cell growth arrest and synergizes with Nutlin-3a-mediated cell death by upregulating p53 and PUMA levels in AML
The evolving landscape underscores the need for clear enforcement, robust pharmacovigilance, and strategic engagement to protect patient safety and preserve brand integrity
US$ 24.50
US$ 27.91
US$ 24.78
